Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.72 |
| ▸ | NAE1 | Q13564 | 4/20 | 0.72 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | PPARG | P37231 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639019 | 0.89 | NAE1 (0.78) | AGTR1NAE1AGTR2CYP3A4ADORA3 | |
| SCHEMBL30007290 | 0.86 | NAE1 (0.74) | AGTR1NAE1AGTR2CYP3A4ADORA3 | |
| SCHEMBL1020471 | 0.86 | NAE1 (0.74) | AGTR1NAE1AGTR2CYP3A4ADORA3 | |
| SCHEMBL21116097 | 0.86 | NAE1 (0.74) | AGTR1NAE1AGTR2CYP3A4ADORA3 | |
| SCHEMBL14192227 | 0.85 | AGTR2 (0.55) | AGTR1NAE1AGTR2CYP3A4ADORA3 | |
| SCHEMBL24819609 | 0.85 | AGTR1 (0.72) | AGTR1NAE1AGTR2CYP3A4ADORA3 | |
| SCHEMBL469652 | 0.85 | NAE1 (0.76) | AGTR1NAE1AGTR2CYP3A4ADORA3 | |
| SCHEMBL8294487 | 0.84 | KDM4E (0.61) | AGTR1NAE1AGTR2CYP3A4ADORA3 | |
| SCHEMBL21302261 | 0.84 | NAE1 (0.75) | AGTR1NAE1AGTR2CYP3A4ADORA3 | |
| Candesartan Cilexetil SCHEMBL3968703 | 0.84 | NAE1 (0.79) | AGTR1NAE1AGTR2CYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139866-B1 | CRYSTALLINE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYL 1-((2'-CYANOBIPHENYL-4-YL)METHYL)-2-ETHOXY-1H-BENZO[D]IMIDAZOLE-7-CARBOXYLATE AND A PROCESS FOR ITS PREPARATION | KRKA D D NOVO MESTO (SI) | 2011-01-12 | — | — | EP | claimed |
| EP-2139866-B1 | CRYSTALLINE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYL 1-((2'-CYANOBIPHENYL-4-YL)METHYL)-2-ETHOXY-1H-BENZO[D]IMIDAZOLE-7-CARBOXYLATE AND A PROCESS FOR ITS PREPARATION | KRKA D D NOVO MESTO (SI) | 2011-01-12 | — | — | EP | disclosed |
| US-7868180-B2 | Process for the preparation of sartan derivatives and intermediates useful in such process | KRKA, D.D. NOVO MESTO (SI) | 2011-01-11 | — | — | US | disclosed |
| EP-2139866-A2 | CRYSTALLINE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYL 1-((2'-CYANOBIPHENYL-4-YL)METHYL)-2-ETHOXY-1H-BENZO[D]IMIDAZOLE-7-CARBOXYLATE AND A PROCESS FOR ITS PREPARATION | KRKA, D.D., Novo Mesto (SI) | 2010-01-06 | — | — | EP | disclosed |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | KRKA, D.D. NOVO MESTO (SK) | 2008-12-18 | — | — | US | disclosed |
| WO-2008129077-A2 | CRYSTALLINE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYL 1-((2'-CYANOBIPHENYL-4-YL)METHYL)-2-ETHOXY-1H-BENZO[D]IMIDAZOLE-7-CARBOXYLATE AND A PROCESS FOR ITS PREPARATION | KRKA, D.D. NOVO MESTO (SI) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | MC5R, NPY5R, ADRA1D | AGTR1 283/4885NAE1 1839/4885AGTR2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.